Mar 4, Cannabis (marijuana, pot, weed, grass etc.) is a widely used recreational and medicinal drug. In fact, cannabis use dates far back in ancient. Jul 17, Cannabis oil has been on the minds of men with prostate cancer. It seems that many people want to know if cannabis oil can cure prostate. Cannabis and cannabinoids have often been an issue of much polemics in the have been established to treat bone metastatic prostate cancer; some focus on.
Cancer? With Can Prostate Help CBD
Doctors also believe that high levels of testosterone increase the risk, while lack of exercise is also a risk factor. For example, Stage I prostate cancer could involve radiation therapy.
In stage III, you may require external radiation plus hormone therapy. Because the range of treatments varies, so does the range of side effects, which can include:. While the majority of treatments for localized prostate cancer are excellent, an increasing number of men are looking at CBD as a natural alternative, with the hopes of deviating away from the potential side effects of pharmaceutical medications.
Cannabis has been championed as a means of easing the effects of chemotherapy for some time, but exciting new research suggests that it could also be capable of slowing — or altogether decreasing — the progression of cancer cells.
In , one of the first studies of its kind looked at the impact of THC on nine patients with a type of brain tumor called glioblastoma multiforme. Regarding cannabis and prostate cancer, positive results in lab tests on animals have led to the publishing of a significant paper in In it, researchers claim that pre-clinical evidence was sufficient to warrant clinical trials of cannabinoid medicines as anti-cancer treatments. The paper cited a study which suggested that prostate cancer cells have increased expression for cannabinoid receptors, or in other words, that they may be prone to the influence of active therapeutic cannabis compounds.
Once again, it all comes down to the impact of the endocannabinoid system ECS , or more pertinently, the impact of weed on the ECS. The excessive amount of receptors found on prostate cancer cells suggest that there may be a correlation between cancer cell proliferation and endocannabinoid deficiency , though this will remain speculation until more studies are carried out.
Androgens are male sex hormones which include testosterone that cause the growth of prostate cells. Some studies have suggested that marijuana produces anti-androgenic effects.
Perhaps the most exciting news of all relates to the potential use of CBD to fight prostate cancer. The British Journal of Pharmacology published a study in which discovered that other cannabis compounds besides THC had anti-tumor effects when tackling prostate cancer cells, and in some tests, CBD actually resulted in the self-destruction of cancer cells.
Moreover, treatment with cannabinoids reduced the viability of prostate cancer cells, with CBD appearing to have a significant role in the overall process. If you have Stage I prostate cancer and are considering cannabis — or CBD in particular — as a realistic treatment option, then we invite you to visit our website to find out more about some of the best CBD sellers on the market.
We offer independent reviews and ensure that only the best companies are represented. If dubious firms are selling CBD and believe us when we say that many are , we will let you know. Research on marijuana, CBD and prostate cancer faces the same problem as all weed-related research, which is an inherent lack of funding.
At the time of writing, there are still 20 states where it is illegal to consume marijuana for medicinal purposes. Since cannabis is still a controlled substance and a Schedule I drug, the level of research into its efficacy for prostate cancer — or any other condition for that matter — is limited. However, the small amount of research that has filtered through has been positive, and is indeed encouraging for those men currently suffering from prostate cancer.
Lastly, we should point out a couple of important things. First, while CBD could help slow the progression of prostate cancer cells or even aid in their programmed self-destruction, you should not rely on it at this point in place of your doctor-recommended medications. After all, there is a big difference between treating nausea, and treating cancer. Homemade oil is usually filled with toxins , and it is very unlikely that it will help combat your prostate cancer any more than a filtered, pure CBD oil would.
Will you please provide the link to this: However, the endocannabinoid signaling system has only been the focus of medical research and considered a potential therapeutic target in recent times. Two different cannabinoid receptors have been described from mammalian tissues: The frequently held view of cannabis and its related products as drugs of abuse have slowed progress in the development of studies designed to take advantage of the properties of cannabinoid derivatives for therapeutic purposes.
The antagonizing effect of cannabinoids in the male reproductive system and physiology can be dated to where experimental models in male rats showed depression of spermatogenesis[ 21 ] and decrease in circulating testosterone levels.
In recent years, cannabinoids and their derivatives have drawn renewed attention due to the discovery of diverse pharmacologic activities such as cell growth inhibition, anti-inflammatory effects, and tumor regression. When the same cells were pretreated with cannabinoid receptor antagonists SR CB1 antagonist or SR CB2 antagonist , the coadministration of WIN, had no effect on cell viability, exhibiting a significant protective effect.
Androgens are involved in the maintenance and progression of prostate cancer, where the androgen receptor is assumed to be the essential mediator for androgen action.
Curiously enough it was determined that high cannabinoid CB1 receptor immunoreactivity is associated with greater disease severity and poorer outcome in prostate cancer patients. Patients with high CB1 receptor immunoreactivity showed a significantly worse survival rate than those with low CB1 receptor immunoreactivity hazard ratio 2. A possible explanation for these results that is in synch with the cell line data is that the expression of CB1 receptors is regulated by the local endocannabinoid release.
The author's conclusion in this scenario was that a low endocannabinoid tone would allow for an increased rate of proliferation, resulting in a compensatory increase in surface expression of CB1 receptors. Cannabinoid CB1 receptors are found mainly in the central nervous system and, in less abundance, in certain peripheral tissues.
Activation of presynaptic CB1 receptors in different brain regions or on primary afferents inhibits the release of neurotransmitters by decreasing calcium conductance and by increasing the conductance of potassium. DeltaTHC is the substance with the greatest psychoactive potency of the natural cannabinoids and exhibits the greatest analgesic activity. Studies with CBD derivatives developed to inhibit peripheral pain responses and inflammation after binding to cannabinoid receptors have been described.
Interestingly, some of these CBD derivatives did not have central nervous system effects, but maintained their antinociceptive and anti-inflammatory properties. This means that centrally inactive synthetic CBD analogues may be candidates for the development of analgesic and anti-inflammatory drugs for peripheral conditions[ 53 ] without major central nervous system alterations of the sensorium.
In animal models of cancer bone pain, synthetic cannabinoids reduced hyperalgesia by a CB1 receptor-mediated effect and possibly at the peripheral CB2 receptor. In some models, cannabinoids were superiorly effective in cancer pain when compared with other pain types. Clinical trials have shown that nonselective cannabinoid receptor agonists are relatively safe and therapeutically efficacious, however, inducing also psychotropic side effects.
Cannabinoid efficacy has also been studied clinically in cancer pain. Initial studies quantified the modest efficacy of oral 20 mg D9-THC equivalent to mg codeine with some sedation, dizziness, and confusion.
Nabilone did not significantly increase adverse effects compared with the control group, and this fact could be attributed to the concurrent decrease in opioid dose. Uncontrolled pain can cause unnecessary suffering, decreased ability to cope with illness, interference with daily activities and extended hospital admissions, and decreasing overall quality of life. Step 1 of the ladder is for patients with mild to moderate cancer-related pain.
These should first be treated with acetaminophen or a nonsteroidal antiinflammatory agent NSAID , possibly combined with an adjuvant drug that provides additional analgesia i. Step 2 describes patients with moderate or severe pain, including those who do not achieve adequate relief after a trial of an NSAID alone; these should be treated with an opioid. The analgesic ladder promoted the doctrine of using an opioid of inferior analgesic properties i.
On both steps 2 and 3, combination therapy that includes an NSAID or other drugs to enhance analgesia or treat side effects is advocated. The combination of two antinociceptive drugs acting through different specific receptor systems provides major benefits.
When synergistic substances are given in combination, the required dose of each agent can be reduced to less than would be explained by mere addition of individual effects. The clinical benefit of this property is fundamental in analgesic treatments because effective pain relief can be achieved with minor, fewer, or no side effects.
Chronic pain is a difficult subject to approach both for the patient and the treating physician and, not uncommonly, leads to chronic opiate consumption and dependence. Cannabis has been documented to be one of such measures. As with any therapeutic modality, adverse effects must be taken into account. A number of patients will suffer from these, although most of them will be present within the first days of treatment and attenuate as they adjust to the drug.
Chronic cannabis use does not produce serious cognitive disorders, as occurs with other substances such as alcohol, but it can aggravate preexisting mental disease.
Therefore, treatment with cannabinoid receptor agonist with central actions may be contraindicated, in individuals predisposed to or with current psychiatric disorders.
No human deaths associated to cannabis use have been reported. Prostate cancer is a grave public health problem worldwide. For these reasons, it is fundamental to invest time and intellectual resources into finding new and novel targets for the treatment of prostate cancer. It seems that the studies of Sarfaraz and colleagues lead to the direction that cannabinoids should be considered as agents for the management of prostate cancer, pending support from in vivo experiments.
This would not only make sense from an anti-androgenic point of view but also for men with bone metastatic prostate cancer, perhaps from a pain management or palliative point of view. Among the patients suffering with chronic pain and receiving opioids, one in five abuse prescription controlled substances,[ 69 , 70 ] and it is not difficult to see that opioid dependence and abuse is becoming a public health problem.
Different methods of managing pain should be addressed to avoid these scenarios. The presence of pain in men with advanced prostate cancer is an immediate indication for aggressive management with analgesics, while adequate treatments that address directly the cause of the pain are pursued.
These compounds harbor analgesic properties that aid bone cancer pain, reduce opioid consumption, side effects, and dependence, as well as exhibiting anti-androgenic effects on experimental prostate cancer cells. Cannabis sativa and its main active component deltaTHC have long been used for numerous purposes throughout history including medicinal, textile, and recreational. Since its legal banning in the United States in , it has become an issue of taboo and controversy, frowned upon for its recreational uses and psychotropic effects.
Nonetheless, the endocannabinoid signaling system has recently been the focus of medical research and considered a potential therapeutic target[ 15 — 17 ] since the late s when Howlett and colleagues[ 3 ] identified and characterized the distinct cannabinoid receptor in rat brain. If the hypothesis is supported by in vivo experiments. It is our conclusion that it would be of interest to conduct clinical trials involving medicinal cannabis or other cannabinoid agonists, comparing clinical markers such as PSA with controls, especially in men with bone metastatic prostate cancer, whom would not only benefit from the possible anti-androgenic effects of cannabinoids but also from analgesia of bone pain, improving quality of life, while reducing narcotic consumption and preventing opioid dependence.
National Center for Biotechnology Information , U. Journal List Indian J Urol v. Ramos and Fernando J.
Author information Copyright and License information Disclaimer. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3. This article has been cited by other articles in PMC. Abstract Prostate cancer is a global public health problem, and it is the most common cancer in American men and the second cause for cancer-related death.
Androgen antagonists, cannabis, cannabinoids, investigational therapies, prostatic neoplasms. Prostate cancer Prostate cancer is the most common cancer in American men except for non-melanoma skin cancer.
Role of cannabinoids in male physiology Cannabis is a bushy plant with palmate leaves and clusters of small green flowers, and it grows wild in regions of tropical weather and can attain up to 3 m height. Current basic science research In recent years, cannabinoids and their derivatives have drawn renewed attention due to the discovery of diverse pharmacologic activities such as cell growth inhibition, anti-inflammatory effects, and tumor regression.
Cannabinoids in cancer pain management Cannabinoid CB1 receptors are found mainly in the central nervous system and, in less abundance, in certain peripheral tissues. Footnotes Source of Support: Nil Conflict of Interest: CA Cancer J Clin. Determination and characterization of a cannabinoid receptor in rat brain.
What we know and what we need to know. Annual report to the nation on the status of cancer, , featuring cancer in American Indians and Alaska Natives. Trends in prostate-specific antigen testing from through Annual report to the nation on the status of cancer, , with a special feature regarding survival.
Overview of treatment for advanced prostate cancer. Assessment and management of bone metastases in advanced prostate cancer. Society of Urologic Oncology position statement: Redefining the management of hormone-refractory prostate carcinoma.
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX study. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Mechoulam R, Gaoni Y, Hashish The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. The first twelve thousand years.
Plant, synthetic, and endogenous cannabinoids in medicine. Early medical use of cannabis. Structure of a cannabinoid receptor and functional expression of the cloned cDNA.
CBD oil - dilemma
I have always wondered whether cannabis oil could indeed be a cure for prostate cancer. Unfortunately, I do not see in practice the desired beneficial effect and. Jan 9, for some time, but exciting new research suggests it could be capable of killing cancer cells. Find out how CBD can help treat Prostate Cancer. Sep 2, “The idea that cannabis would influence prostate cancer in a meaningful way sounds more than a little far-fetched to me,” Dr. Juurlink said in a.